The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-14. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
=== Class III === Proteins containing multiple covalently attached heme groups with low redox potential are included in class III. The heme C groups, all bis-histidinyl coordinated, are structurally and functionally nonequivalent and present different redox potentials in the range 0 to −400 mV. Members of this class are e.g. cytochrome c7 (triheme), cytochrome c3 (tetraheme), and high-molecular-weight cytochrome c (Hmc), containing 16 heme groups with only 30-40 residues per heme group. The 3D structures of a number of cyt c3 proteins have been determined. The proteins consist of four or five α-helices and two β-sheets wrapped around a compact core of four non-parallel hemes, which present a relatively high degree of exposure to the solvent. The overall protein architecture, heme plane orientations and iron-iron distances are highly conserved. An example is the photosynthetic reaction centre of Rhodopseudomonas viridis that contains a tetraheme cytochrome c subunit.
Several studies have determined the potential use of PCSK9 inhibitors in the treatment of hyperlipoproteinemia (commonly called hypercholesterolemia). Furthermore, loss-of-function mutations in the PCSK9 gene result in lower levels of LDL and protection against cardiovascular disease. Drugs can inhibit PCSK9, leading to lowered circulating LDL particle concentrations. Since LDL particle concentrations are thought by many experts to be a driver of cardiovascular disease like heart attacks, it is plausible that these drugs may also reduce the risk of such diseases. Clinical studies, including phase III clinical trials, are now underway to describe the effect of PCSK9 inhibition on cardiovascular disease, and the safety and efficacy profile of the drugs. Among those inhibitors under development in December 2013 were the antibodies alirocumab, evolocumab, 1D05-IgG2 (Merck), RG-7652 and LY3015014, as well as the RNAi therapeutic inclisiran. PCSK9 inhibitors are promising therapeutics for the treatment of people who exhibit statin intolerance, or as a way to bypass frequent dosage of statins for higher LDL concentration reduction. A review published in 2015 concluded that these agents, when used in patients with high LDL-particle concentrations (thus at greatly elevated risk for cardiovascular disease) seem to be safe and effective at reducing all-cause mortality, cardiovascular mortality, and heart attacks.
Official website (in Italian) Tourism webpage How to reach Turin? Turin Museums Turin City Card This article incorporates text from a publication now in the public domain: Benigni, Umberto (1912). "Turin". Catholic Encyclopedia. Vol. 15. Turin travel guide from Wikivoyage
Further work by Crick and co-workers showed that the genetic code was based on non-overlapping triplets of bases, called codons, allowing Har Gobind Khorana, Robert W. Holley, and Marshall Warren Nirenberg to decipher the genetic code. These findings represent the birth of molecular biology.
=== Export markets === The 1985 Familia spawned a Ford Laser twin sold in the Asia-Pacific. The Laser saloon and wagon were nearly identical to the Familia but with a Ford grille. By contrast the Laser hatchback model, which was sold in the U.S. as the Mercury Tracer used completely different panels from the Familia's. Engines (European models unless otherwise noted):
Sources: en.wikipedia.org
== N == David Nachmansohn (1899–1983). German biochemist at Columbia, responsible for elucidating the role of phosphocreatine in energy production in muscles. Member Natl. Acad. Sci. USA Joseph Needham FRS (1900–1995). British biochemist at Cambridge, historian and sinologist, noted for embryology and morphogenesis, and also in Chinese science. Eva J. Neer (1937–2000). American physician and biochemist at Harvard, who researched on G-protein cell biology. Member of the National Academy of Medicine. Joe Neilands (1921–2008). Canadian-born American biochemist and political activist at UC Berkeley, known for studies of microbial iron transport, and as author, with Paul K. Stumpf of Outlines of Enzyme Chemistry. Carl Neuberg (1877–1956). German biochemist at the University of Berlin, a pioneer in the study of metabolism. Michael Neuberger (1953–2013). British biochemist and immunologist at Cambridge University known for delineating the role of DNA deamination in immunity. Hans Neurath (1909–2002). American protein chemist at the University of Washington. He was the Founding editor of Biochemistry, which he edited for 30 years (1961–1991). Member Natl. Acad. Sci. USA. Eric Newsholme (1935–2011). British biochemist at the University of Oxford who specialised in human metabolism. Hermann Niemeyer (1918–1991). Chilean biochemist. National Prize of Science (Chile). Member of the Academy of Science of Chile. Marshall Warren Nirenberg (1927–2010).
The energy released by the Hiroshima bomb explosion (about 15 kt TNT equivalent, or 6×1013 J) is often used by geologists as a unit when describing the energy of earthquakes, volcanic eruptions, and asteroid impacts. Prior to the detonation of the Hiroshima bomb, the size of the Halifax Explosion (about 3 kt TNT equivalent, or 1.26×1013 J), was the standard for this type of relative measurement. Each explosion had been the largest known artificial detonation to date.
== Clinical significance == There are at least 25 enzymes and specific transport proteins in the β-oxidation pathway. Of these, 18 have been associated with human disease as inborn errors of metabolism. In addition to genetic fatty-acid metabolism disorders, studies indicate that lipid disorders are involved in diverse aspects of tumorigenesis, and fatty acid metabolism makes malignant cells more resistant to a hypoxic environment. Accordingly, cancer cells can display irregular lipid metabolism with regard to both fatty acid synthesis and mitochondrial fatty acid oxidation (FAO) that are involved in diverse aspects of tumorigenesis and cell growth. Several specific β-oxidation disorders have been identified.
As a legacy of SVB's Boston Private acquisition, it provided free banking services to many nonprofits in San Mateo County, California, who have needed to redirect donations to alternative bank accounts. Ahmad Thomas, CEO of the Silicon Valley Leadership Group, of which the bank was a member, described the failure as a setback for the San Francisco Bay Area's startup ecosystem and noted that it would be difficult to replicate the bank's business model.
Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome (sometimes referred to as TANGO2 Deficiency) is a rare metabolic and genetic disorder which is caused by mutation in a gene TANGO2. Main signs of this disorder are: Intellectual disability, ataxia, underactive thyroid, and life-threatening episodes of metabolic and cardiac crises, rhabdomyolysis. The syndrome affects about 1/1 000 000 births, with about 110 cases having been reported worldwide (at the time of articles publication as February 28, 2025).
Sources: en.wikipedia.org
Albert Grünwedel, one of the German discovers of the Kizil Caves, found in Saint-Peterburg a 13th-century Tibetan text related to Kucha and the Kizil Caves, including a map, which describes the caves from the perspective of Tantric Buddhism. According to the Tibetan text, the paintings in some of the caves were commissioned by a Tokharian (Thogar) king called "Mendre" (probably Māndhātṛ) with the advice of Anandavarman, a high-ranking monk. The king ordered an Indian artist, Naravahanadatta, and a Syrian artist, Priyaratna, with their disciples to paint the caves. The neighbouring Khotanese kings Vijayavardhana and Murlimin also assisted with the painting of another cave by sending artists to the site.
This money was used for improvements and security enhancements at research and storage facilities. Safety of nuclear facilities in Russia has been significantly improved since the stabilization of political and economical turmoil of the early 1990s. For example, in 1993 there were 29 incidents ranking above level 1 on the International Nuclear Event Scale, and this number dropped under four per year in 1995–2003. The number of employees receiving annual radiation doses above 20 mSv, which is equivalent to a single full-body CT scan, saw a strong decline around 2000. In November 2015, the Russian government approved a federal program for nuclear and radiation safety for 2016 to 2030 with a budget of 562 billion rubles (ca. 8 billion USD). Its key issue is "the deferred liabilities accumulated during the 70 years of the nuclear industry, particularly during the time of the Soviet Union". About 73% of the budget will be spent on decommissioning aged and obsolete nuclear reactors and nuclear facilities, especially those involved in state defense programs; 20% will go in processing and disposal of nuclear fuel and radioactive waste, and 5% into monitoring and ensuring of nuclear and radiation safety.
The limitations of 3D bioprinting are associated with physiologically irrelevant morphology and unsuccessful histological evaluation methods. 3D bioprinting contributes to significant advances in the medical field of tissue engineering by allowing for research to be done on innovative materials called biomaterials. Some of the most notable bioengineered substances are usually stronger than the average bodily materials, including soft tissue and bone. These constituents can act as future substitutes, even improvements, for the original body materials. In addition, the Defense Threat Reduction Agency aims to print mini organs such as hearts, livers, and lungs as the potential to test new drugs more accurately and perhaps eliminate the need for testing in animals. For bioprinted food like meat see #Food and drink.
Gerald Kaufman (21 June 1930 – 26 February 2017) politician, journalist, broadcaster and author who served as a minister throughout the Labour government of 1974 to 1979; elected as member of parliament (MP) at the 1970 general election, he became Father of the House and served until 2017; served as chair of the Culture, Media and Sport Committee; was knighted in 2004; was assistant general secretary of Fabian Society; was leader writer on Daily Mirror and journalist on New Statesman; also worked as television writer, contributing to BBC Television's satirical programme That Was The Week That Was; was member of Poale Zion (later the Jewish Labour Movement) but became disillusioned with Israel because of its treatment of the Palestinian territories. Michael Kauffmann FBA (5 February 1931 – 30 June 2023), art historian and author of numerous scholarly monographs and academic publications; Director of the Courtauld Institute, London and Fellow of the British Academy; held posts at the Warburg Institute, Manchester City Art Gallery, and the Victoria and Albert Museum; was son of noted art historian, art dealer and scholar Arthur Kauffmann, both of German Jewish ancestry; died on 30 June 2023, at the age of 92. Adam Kay (writer) (born 12 June 1980) comedy writer, author, comedian and former doctor. His television writing credits include Crims, Mrs. Brown's Boys and Mitchell and Webb. He is best known as author of the number-one bestselling book This Is Going to Hurt.
=== Assisted reproduction === PRP can be inoculated into the uterine cavity, to improve endometrial receptivity in cases of refractory endometrium. Studies have reported that intrauterine inoculation of PRP before embryo transfer can thicken the endometrium and improve reproductive prognosis. PRP has been studied for the management of Asherman's Syndrome. PRP can be inoculated experimentally into the ovary to promote ovarian tissue regeneration. The main applications would be in cases of diminished ovarian reserve or premature ovarian failure. A 2023 retrospective observational study reported PRP's effectiveness in rejuvenating ovarian fertility and viability in terms of "the influence of intraovarian injection of autologous PRP on the levels of E2". and pregnancy outcome in women treated with PRP who had a history of infertility, hormonal abnormalities, an absence of menstrual cycle, and premature ovarian failure in a single centre." A 2024 review showed that PRP is beneficial when used as intraovarian injections for women with decreased fertility. PRP used for fertility trouble increases AFC, number of cleavage embryos, and improves cancellation rate in women with poor ovarian reserve. However, "Although there was an improvement of baseline hormones (anti-Müllerian hormone, follicle-stimulating hormone, and estradiol) after intraovarian injection of PRP, this improvement failed to reach statistical significance (except the improvement of serum AMH analyzed in quasi-experimental studies)."
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.